Ivermectin Shows Promise in Lab, But Clinical Evidence for Cancer Treatment Remains Absent

Ivermectin is a legitimate antiparasitic drug with a remarkable history. In the 1970s, Japanese microbiologist Satoshi Ōmura and his team at the Kitasato Institute screened thousands of soil samples searching for medically useful compounds. A sample from near a golf course in Ito City, Shizuoka Prefecture, yielded Streptomyces avermitilis, a bacterium that produced a family of compounds called avermectins. At Merck's laboratories in the United States, parasitologist William C. Campbell and colleagues investigated these compounds and discovered powerful activity against parasitic worms. Scientists chemically modified avermectin B1 to create ivermectin, a more potent derivative. The drug entered veterinary medicine in 1981 and soon proved transformative in human medicine, particularly against Onchocerca volvulus, the parasite responsible for river blindness. Clinical studies in the early 1980s demonstrated that ivermectin could dramatically reduce the parasite's microfilariae and help prevent the inflammation and vision loss associated with the disease. France approved it for human use in 1987. The medication became central to large-scale global programs targeting onchocerciasis and lymphatic filariasis, diseases affecting millions in tropical and resource-limited regions. In 2015, Ōmura and Campbell received the Nobel Prize in Physiology or Medicine for their discovery, recognized for benefiting hundreds of millions of people.

Over the past several years, ivermectin has attracted attention in oncology. Laboratory studies have reported effects on cancer-cell proliferation, apoptosis, signaling pathways, drug resistance, and the tumor microenvironment. Researchers have observed that ivermectin can inhibit cancer-cell proliferation, migration, and invasion, and induce apoptosis across several tumor types, including breast, colorectal, lung, gastric, ovarian, melanoma, prostate, pancreatic, and liver cancers. A 2025 review summarized evidence suggesting that ivermectin can influence several oncogenic signaling networks, including Wnt/β-catenin, PI3K/Akt/mTOR, and STAT3, while also affecting mitochondrial function and cellular survival pathways. Some researchers have proposed that ivermectin interferes with signaling pathways involved in cancer-cell survival and proliferation, including PAK1, Akt/mTOR, and STAT3. Other proposed mechanisms involve the Wnt/β-catenin pathway and YAP1, which regulate proliferation, differentiation, and tumor development. Experimental studies have reported that ivermectin can increase reactive oxygen species, alter mitochondrial membrane potential, and activate pathways associated with programmed cell death. A 2021 study in breast cancer models reported that ivermectin could promote features associated with immunogenic cell death and increase immune-cell activity, with enhanced activity when combined with immune checkpoint blockade in experimental models. Researchers have also investigated whether ivermectin could influence mechanisms of drug resistance, including drug-efflux transporters such as P-glycoprotein.

But there is a critical distinction between what happens in a laboratory dish and what happens in a human body. As of 2026, ivermectin is not an approved cancer treatment, and clinical evidence remains absent. Recent reviews describe a substantial gap between promising preclinical findings and evidence from human trials. There is currently no established evidence that ivermectin improves overall survival, progression-free survival, objective tumor response, or quality of life in patients with cancer. A drug can affect cancer cells in vitro and still fail clinically because of pharmacokinetics, toxicity, inadequate tumor exposure, biological heterogeneity, or other factors.

One of the biggest challenges in translating laboratory findings into cancer treatment is determining whether the concentrations of a drug that affect cancer cells can actually be achieved safely in humans. In preclinical experiments, researchers may expose cancer cells directly to a compound at concentrations that produce measurable effects. However, the human body processes drugs differently, and the concentration reached in the bloodstream or inside a tumor may be substantially different from the concentration used in a laboratory experiment. Some anticancer effects reported in experimental studies have occurred at concentrations that may not correspond to exposures achievable with currently approved human dosing. Ivermectin also has physicochemical characteristics that may affect its clinical development, including high lipophilicity and poor aqueous solubility. Researchers must determine whether sufficient drug can reach the tumor while remaining within a safe exposure range. They also need to understand how the drug is absorbed, distributed, metabolized, and eliminated, and whether cancer patients receiving other medications could experience clinically important drug interactions.

Research has begun moving beyond laboratory studies, but clinical investigation remains early. One current example is the ICONIC trial, registered as NCT07487805, which is studying ivermectin in combination with immune checkpoint inhibition in cancer. The trial is not yet recruiting. Its primary objective includes evaluating changes in immune-cell activity, while safety and cytokine changes are among the secondary outcomes. The trial illustrates the current scientific question: researchers are not simply assuming ivermectin works. They are testing whether it can produce measurable biological and clinical effects when combined with established immunotherapy. Earlier clinical work has also explored ivermectin combined with anti-PD-1 therapy in metastatic triple-negative breast cancer. However, the available human data remain too limited to establish efficacy.

The greatest concern is not scientific interest in ivermectin itself, but the use of unproven dosing or formulations outside medical supervision. Ivermectin is an established antiparasitic medication with approved human uses, but human and veterinary formulations are not interchangeable. Veterinary products may contain different concentrations, formulations, or excipients and are not intended for human use. Most importantly, ivermectin is not approved as a cancer treatment, and there is no established anticancer dose or treatment schedule. Taking ivermectin for cancer could expose patients to unnecessary toxicity, interact with other medications, or most importantly delay effective cancer treatment. This is particularly relevant in oncology, where patients may already be receiving several medications and where treatment timing can be clinically important. High or inappropriate doses can cause adverse effects, including gastrointestinal and neurological symptoms.

Ivermectin's reputation as a potential cancer treatment is partly driven by the gap between preclinical research and clinical evidence. When laboratory studies show that a drug can kill cancer cells or slow tumor growth in experimental models, those findings can easily be interpreted online as proof that the drug treats cancer in people. Social media posts, testimonials, and anecdotal reports can further amplify these claims, even when they are not supported by clinical trials. Friends and family members may recommend ivermectin with good intentions, seeing a study, video, or personal story suggesting that ivermectin has anticancer properties and believing they are offering another treatment option. The problem is that a laboratory finding or individual experience cannot establish whether a treatment is effective or safe for cancer patients. The greatest risk is that an unproven treatment may delay or replace effective cancer care. Cancer treatment is often time-sensitive, and postponing surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy, or endocrine therapy can allow disease to progress.

Patients should not replace evidence-based treatments with ivermectin. For patients interested in experimental approaches, the safest path is to discuss the question with their oncology team and, when appropriate, consider participation in a properly designed clinical trial. The most important question is not whether ivermectin kills cancer cells in a laboratory—it can under certain experimental conditions. The clinically relevant question is whether ivermectin safely improves outcomes for people with cancer. That answer remains unknown.